These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26184008)

  • 21. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment.
    Jewell ML; McCauliffe DP
    J Am Acad Dermatol; 2000 Jun; 42(6):983-7. PubMed ID: 10827400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimalarial drugs, systemic lupus erythematosus and pregnancy.
    Parke AL
    J Rheumatol; 1988 Apr; 15(4):607-10. PubMed ID: 3397970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.
    Chang AY; Piette EW; Foering KP; Tenhave TR; Okawa J; Werth VP
    Arch Dermatol; 2011 Nov; 147(11):1261-7. PubMed ID: 21768444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resistance to hydroxychloroquine due to smoking in a patient with lupus erythematosus tumidus.
    Hügel R; Schwarz T; Gläser R
    Br J Dermatol; 2007 Nov; 157(5):1081-3. PubMed ID: 17854374
    [No Abstract]   [Full Text] [Related]  

  • 25. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study.
    Francès C; Cosnes A; Duhaut P; Zahr N; Soutou B; Ingen-Housz-Oro S; Bessis D; Chevrant-Breton J; Cordel N; Lipsker D; Costedoat-Chalumeau N
    Arch Dermatol; 2012 Apr; 148(4):479-84. PubMed ID: 22508872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus.
    Pelle MT; Callen JP
    Arch Dermatol; 2002 Sep; 138(9):1231-3; discussion 1233. PubMed ID: 12224986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Quinacrine in the treatment of cutaneous lupus erythematosus: practical aspects and a case series].
    González-Sixto B; García-Doval I; Oliveira R; Posada C; García-Cruz MA; Cruces M
    Actas Dermosifiliogr; 2010; 101(1):54-8. PubMed ID: 20109393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antimalarial agents and lupus.
    Wallace DJ
    Rheum Dis Clin North Am; 1994 Feb; 20(1):243-63. PubMed ID: 8153401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial.
    Yokogawa N; Eto H; Tanikawa A; Ikeda T; Yamamoto K; Takahashi T; Mizukami H; Sato T; Yokota N; Furukawa F
    Arthritis Rheumatol; 2017 Apr; 69(4):791-799. PubMed ID: 27992698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival.
    Sisó A; Ramos-Casals M; Bové A; Brito-Zerón P; Soria N; Muñoz S; Testi A; Plaza J; Sentís J; Coca A
    Lupus; 2008 Apr; 17(4):281-8. PubMed ID: 18413408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Experience with the use of hydroxychloroquine for the treatment of lupus erythematosus.
    Momose Y; Arai S; Eto H; Kishimoto M; Okada M
    J Dermatol; 2013 Feb; 40(2):94-7. PubMed ID: 23216212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cutaneous lupus profundus].
    Khalfallah N; Azzabi S; Ben Hassine L; Fathallah L; Kooli C; Fazâa B; Hamza M; Haddad A
    Tunis Med; 2003 Feb; 81(2):134-9. PubMed ID: 12708181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review.
    Wallace DJ
    Lupus; 1996 Jun; 5 Suppl 1():S59-64. PubMed ID: 8803913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antimalarials in lupus erythematosus treatment].
    Woźniacka A
    Przegl Lek; 2002; 59(3):179-82. PubMed ID: 12184034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cutaneous lupus erythematosus: update of therapeutic options part I.
    Kuhn A; Ruland V; Bonsmann G
    J Am Acad Dermatol; 2011 Dec; 65(6):e179-93. PubMed ID: 20739095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Systemic lupus erythematosus therapy. Antimalarials in inflammatory diseases].
    Yebra-Bango M; Tutor-Ureta P
    Rev Clin Esp; 2004 Nov; 204(11):565-6. PubMed ID: 15511401
    [No Abstract]   [Full Text] [Related]  

  • 37. Treating lupus patients with antimalarials: analysis of safety profile in a single-center cohort.
    Spinelli FR; Moscarelli E; Ceccarelli F; Miranda F; Perricone C; Truglia S; Garufi C; Massaro L; Morello F; Alessandri C; Valesini G; Conti F
    Lupus; 2018 Sep; 27(10):1616-1623. PubMed ID: 29954281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimalarial drug-induced aquagenic-type pruritus in patients with lupus.
    Jiménez-Alonso J; Tercedor J; Jáimez L; García-Lora E
    Arthritis Rheum; 1998 Apr; 41(4):744-5. PubMed ID: 9550488
    [No Abstract]   [Full Text] [Related]  

  • 39. Increased CD69+CCR7+ circulating activated T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials.
    Zeidi M; Chen KL; Patel J; Desai K; Kim HJ; Chakka S; Lim R; Werth VP
    Lupus; 2022 Apr; 31(4):472-481. PubMed ID: 35258358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.
    Cavazzana I; Sala R; Bazzani C; Ceribelli A; Zane C; Cattaneo R; Tincani A; Calzavara-Pinton PG; Franceschini F
    Lupus; 2009 Jul; 18(8):735-9. PubMed ID: 19502270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.